Sep 09, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
TEM Q2 Revenues Soar Amid Coverage Issues: Time to Buy, Hold or Sell?
Tempus AI posts 89.6% Q2 revenue growth, raises 2025 sales outlook again, and sees positive adjusted EBITDA ahead. What is the investment outlook?
Aug 25, 2025 • Benzinga
SOMEWHAT-BULLISH
Biobanking Market is expected to generate a revenue of USD 2.11 Billion by 2031, Globally, at 9.89% CAGR: Verified Market Research®
Lewes, Delaware, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- The Global Biobanking Market Size is projected to grow at a CAGR of 9.89% from 2024 to 2031, according to a new report published by Verified Market Research®.
Aug 19, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Profusa Welcomes Former Acting U.S. Veterans Affairs Secretary Peter O'Rourke as Lead Independent Director; Adds Seasoned Finance Executive Fred Knechtel as CFO
Board addition served in the Trump Administration, overseeing 1,300 facilities serving more than 9 million veterans. New CFO has led finance and operations at companies including Northrop Grumman, Stanley Black & Decker, and DuPont ...
Aug 05, 2025 • Motley Fool
SOMEWHAT-BULLISH
Azenta ( AZTA ) Q3 EPS Jumps 36%
Azenta ( NASDAQ:AZTA ) , a provider of life sciences solutions focusing on sample management and genomics services, released its third-quarter fiscal 2025 results on August 5, 2025. The headline: Non-GAAP profitability beat expectations, but GAAP revenue was flat and missed analyst forecasts.
Mar 06, 2025 • Zacks Commentary
NEUTRAL
Is the Options Market Predicting a Spike in Azenta ( AZTA ) Stock?
Investors need to pay close attention to Azenta (AZTA) stock based on the movements in the options market lately.
Dec 19, 2024 • Zacks Commentary
SOMEWHAT-BULLISH
Azenta ( AZTA ) Surges 7.2%: Is This an Indication of Further Gains?
Azenta (AZTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.